Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 30517896.
- Also identified by DOI 10.1016/j.cmet.2018.11.010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Heart failure and renal disease remain significant complications in people with type 2 diabetes (T2D). Recent outcome studies with sodium-glucose cotransporter-2 (SGLT2) inhibitors have provided increasing insights, with the latest reporting trial DECLARE-TIMI 58 (Wiviott et al., 2018), pointing toward a role for these agents in the primary prevention of cardio-renal complications in T2D.
Medical subject headings
- Diabetes Mellitus, Type 2